A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
NCT06703606
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Severe Hemophilia A
Interventions
DRUG:
MARSTACIMAB
Sponsor
Pfizer